MyDx, Inc. announced it has agreed on terms and entered into a Letter of Intent to partner with Highsmen Genetics to form a new Exclusive Joint Venture. The technology behind Highsmen to develop stable customized genetic strains for certain effects is expected to help MYDX360 customers realize additional brand loyalty through end-user input in the MyDx App that will now influence the flower breeding programs that power the product lines they are consuming. MYDX and HIGHSMEN have agreed to enter into a 50:50 Exclusive Joint Venture where the HIGHSMEN Genetics Technology will be offered exclusively to MYDX360 customers. Access will be limited and initial MYDX360 customers will be offered the service on a first come basis. Initially, Highsmen and MyDx will focus on producing a stable 1:1 THC to CBD genetic line developed by HIGHSMEN. The goal is to be able to produce a custom flower strain with custom cannabinoids and terpenes that can be tailored for specific end use applications, such as sleep or pain relief, which will power natural products developed and offered to MyDx360 customers. MyDx will continue the breeding program with HIGHSMEN with the goal of creating a custom flower strain for every physiological effect MyDx and its MyDx360 customers are seeking for their respective markets, backed by customer feedback via the MyDx App. MyDx360 customers are also expected to be able to leverage the combined networks of licensed producers and manufacturers to produce the necessary volumes of customized flower at more cost efficient prices. Additionally, MyDx will equip HIGHSMEN with the CannaDx handheld analyzer and tracking App in order to catalog the genetic lines, strain lineage, input from consumers, and chemical makeup that function within the breeding program. MyDx360 customers are expected to able to utilize this service in products as soon as the first quarter of 2018 with custom flower being deployed as early the second quarter of 2018.